An interventional study of STELLA-R Curriculum and Unrestricted Access in Caregiver Burden, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-23.
Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 228 studies in Caregiver Burden with a site in United States — 59 open to participants now, 71 under way, 1 of them phase 3. Caregiver Burden · United States.
Among the 228 studies in Caregiver Burden with a site in United States, this one is the 32nd largest by planned enrollment of the 208 interventional ones that give a count, is one of 25 that started in 2024, is one of 190 with no phase, reaches primary completion later than 15 of the 70 other live ones, and was the 166th registered.
503 studies on the registry are indexed under Caregiver Burden; 166 are open to participants now.
Browse Caregiver Burden studies →59 of the 228 studies in Caregiver Burden with a site in United States are open now. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+ · Healthy volunteers
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Caregiver Burden studies recruiting now, 69 (77%) set no upper age limit and 7 (8%) stop at 75 or younger; 8 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
228 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 4 · Phase 4 2
First in 2000; this study’s year is marked. 25 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 238 is above the median of 73 across 404 interventional studies indexed under Caregiver Burden.
Median enrollment 60 across the 208 interventional studies, 47 across the 19 observational. Of the 140 that completed or were terminated, 54 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 228 have an industry lead sponsor. The 10 most frequent:
Oregon Health and Science University is the lead sponsor of 697 studies on the registry; 129 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 39 (74%) have results posted.
Oregon Health and Science University has 6 studies filed under Caregiver Burden — fewer than ten, so there is no comparison to draw.
29 of the studies in Caregiver Burden with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06167746Phase 3University of PennsylvaniaiCare4Me Transitions | 2027-09-30 |
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT06099197Indiana UniversityI-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms in Hispanic Individuals | 2026-11 |
| NCT07594730New York State Psychiatric InstituteBrief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems | 2026-12-01 |
| NCT06460012Oregon Health and Science UniversitySupport Via Technology: Living and Learning With Advancing Dementia-REVISED | 2026-12-01 |
Add all 29 to your calendar (.ics) → With an account.
Among the 228 studies in Caregiver Burden with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
STELLA-R is a multicomponent, self-directed, online intervention designed to facilitate effective management of behavioral and psychological symptoms that are common in many types of dementia. The curriculum instructs care partners to use the ABC approach, a cognitive behavioral technique that teaches care partners to describe a Behavior, then consider the Activators and Consequences of a care recipient behavior. The goal of this intervention is to reduce care partner burden and decrease reactivity to upsetting behaviors.
Providing care for a family member with Alzheimer's disease and related dementias (ADRD, aka, "dementia") is both rewarding and risky. Care partners exposed to chronic stress, often over years, are susceptible to physical and psychological ailments. Dementia involves neurodegeneration and those affected typically depend on family members for support and physical care. The "care partners" for those with dementia often experience concerning psychological and physical outcomes due to the demands of caregiving. No matter what type of dementia, most care partners experience some burden. The burden is often related to the behavioral symptoms that most people with dementia experience.
Care partners for those with dementia experience burden, grief, exhaustion and physical ailments. Programs for these care partners are more available. Effective interventions that reduce care partner burden and health risks are also available, but various factors impede participation, including distance, cost, behavioral symptoms of dementia, stigma and social anxiety. Recognizing the need to reduce barriers to access, scientists have turned to internet-based interventions.
The STELLA suite of research studies addresses the need for easily accessible, effective interventions designed to reduce burden in care partners for those with dementia. These studies examine the acceptability, feasibility, and efficacy of interventions modeled on Teri's psychoeducational behavior change intervention. We have completed two pilot studies for care partners for those with dementia using interventions with the STELLA-R precursor. These studies found early efficacy and acceptability for the intervention. We are currently testing a STELLA intervention which uses objective, technology-based assessments (OHSU IRB # 19306) and another, larger study which tests a STELLA intervention with a large national sample (OHSU IRB # 22288; NIA R01AG067546). In addition, with funding from the Association for Frontotemporal Degeneration (AFTD) we tested a similar intervention (STELLA-FTD) for care partners caring for a family member with frontotemporal dementia (OHSU IRB # 22721).
In all STELLA studies care partners work with professional guides to use the ABC analytic approach to describe a distressing behavior, then identify its activators and consequences. With this information, care partners can develop plans to reduce behavioral symptoms. In this proposed study, we will assess an online version of Tele-STELLA.
STELLA-R is informed by the World Health Organization (WHO) guidance to include rehabilitation science in dementia care to facilitate effective management of the advancing behavioral, communication, physical and social changes that come with progressive neurodegenerative dementias (e.g., Alzheimer's disease, frontotemporal degeneration, Lewy Body dementia). Grounded in self-efficacy theory and foundational research, STELLA-R will train care partners to address current behavioral symptoms and prepare for future ones.
The specific aims of this study are:
Aim 1. Assess feasibility and acceptability of STELLA-R
Aim 2. Compare the efficacy of STELLA-R in reducing care partner reactivity to dementia-related behavioral symptoms between two groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Care partners start the STELLA-R Curriculum immediately after enrollment.
Behavioral: STELLA-R Curriculum · Behavioral: Unrestricted Access · Behavioral: Limited Access
Care partners start the STELLA-R Curriculum 8 weeks after enrollment.
Behavioral: STELLA-R Curriculum · Behavioral: Unrestricted Access · Behavioral: Limited Access
The STELLA-R curriculum is presented utilizing the ABC analytic approach to address care recipient's distressing behaviors. Using the scaffold of the ABC pyramid, they will receive video instructions on how to fully define the Behaviors they want to address by observing, describing, and writing about them. The care partners will learn to identify the Activators, the triggers for the behaviors. Next, care partners will learn to consider what happens after the behaviors, the Consequences. This is an 8-week self-directed, online weekly curriculum.
Following the STELLA-R curriculum, care partners will receive 8 weeks of unrestricted access to all lessons and resources.
Also known as: Post-Intervention Phase, Review Phase
Experimental and Waitlist Control group will experience 8 consecutive weeks of limited access to the STELLA-R website and resources. Waitlist Control will experience this from Week 1 to Week 8 while the Experimental Group will reach this phase from Week 17 to Week 24.
Also known as: Restricted Access
Revised Memory and Behavior Problems Checklist (RMBPC)
The primary outcome variable, reactivity, will be assessed with the RMBPC, which measures the frequency of care recipient behavioral symptoms and care partner reactions to these behaviors. The RMBPC was chosen because it aligns with our theoretical foundation that assumes burden is a result of care partner reactions to behavioral symptoms. The RMBPC is a 29-item caregiver report measure, 5-point Likert scale with frequency measuring from 0 (never occurred) to 4 (daily or more often) and reactivity measuring from 0 (not at all) to 4 (extremely) for a total score between 0-116 for each subscale (frequency subscale and reactivity subscale). Higher scores indicate greater behavioral problems.
Time frame: Week 1, Week 8, Week 16, Week 24
Feasibility of STELLA-R Intervention
We will assess the feasibility of implementing STELLA-R across Oregon, Washington and Idaho. We will analyze metadata from the STELLA-R website to assess care partner usage of intervention materials. We will assess data from the surveys to characterize the sample, assess program acceptability, and measure treatment fidelity. We will compare demographic information, computer use, health-care usage, behavioral symptom frequency, medication use, care partner reactivity, burden and depression.
Time frame: 10 months
Acceptability of STELLA-R Intervention
For acceptability, we will utilize the STELLA-R Experience Survey which is a 16-item survey on satisfaction, privacy, and ease of use. We will analyze the STELLA-R Experience Survey results using descriptive statistics. We will identify themes of acceptance, or lack thereof, of STELLA-R and the underpinnings of their impressions.
Time frame: Week 24
Fortinsky's Measurement of Family Care Partner Self-Efficacy for Managing Dementia
Self-efficacy, the mediating variable, will be assessed using Fortinsky's measurement of family care partner self-efficacy for managing dementia. Fortinsky's assess the targets in STELLA-R: behavior symptom management and service use. Fortinsky's measurement is a 9-item Likert scale ranging from 1 (not at all certain) to 10 (very certain). Higher scores are associated with fewer depressive symptoms and fewer physical health symptoms.
Time frame: Week 1, Week 8, Week 16, Week 24
Preparedness for Caregiving Scale
The Preparedness for Caregiving Scale is a 10-item Likert scale ranging from 0 (not at all prepared) to 4 (very well prepared). We will measure care partner preparedness for current and future challenges to test the effect of a group-based intervention.
Time frame: Week 1, Week 8, Week 16, Week 24
Ten-Item Personality Inventory (TIPI)
The Ten-Item Personality Inventory is a 10-item Likert scale measure to assess introversion and extraversion. Choices range from 1 (disagree strongly) to 7 (agree strongly) with reverse scoring on items 2, 4, 6, 8 and 10. Scoring on items are as follows: extraversion: 1, 6R; agreeableness: 2R, 7; conscientiousness: 3, 8R; emotional stability: 4R, 9; openness to experiences: 5, 10R. We will use this measure to test the effect of a group-based intervention.
Time frame: Week 1
Personalized Target Behavior Survey
The Personalized Target Behavior Survey measure frequency and reactivity of up to 3 personalized behaviors identified by care partners. We will collect data on the number of ABC plans each care partner writes on the Orbit weekly survey and the STELLA-R website.
Time frame: Week 1, Week 8
Emotional and Physical Strain
The Orbit weekly survey will measure emotional and physical strain for caregivers.
Time frame: Weekly for 6 months
Healthcare Use
The Orbit weekly survey will measure service use and medication use for behavioral symptoms.
Time frame: Weekly for 6 months
Zarit Burden Interview
The Orbit weekly survey will include the Zarit Burden Interview, a 4-item caregiver report measuring care partner burden. This measure is a 5-point Likert scale with a range of 0 (never) to 4 (nearly always) with higher scores meaning greater burden.
Time frame: Weekly for 6 months
The Neuropsychiatric Inventory (NPI-Q)
The NPI-Q with Caregiver Self-Efficacy Scale evaluates 12 behavioral disturbances in dementia. Each domain captures severity of BPSD and caregiver self-efficacy. Severity is rated 1 (mild) to 3 (severe) and self-efficacy is reverse scored from 4 (not at all confident) to 1 (very confident). This measure assesses self-efficacy in addressing specific behavioral symptoms.
Time frame: Week 1, Week 8, Week 16, Week 24
Placement Plan Scale
1-item Likert scale assessment of plans for placement of family member with dementia. Care partners will rate their likelihood of moving their family member with dementia to another living arrangement from 1 (not at all likely) to 5 (very likely).
Time frame: Week 1, Week 8, Week 16, Week 24
Use of Professional Services
A 7-item binary assessment of professional services used to address their family member with dementia's needs in the past 2 months. Care partners will answer Yes or No to using a: dietitian, elder care attorney, occupational therapist, physical therapist, psychologist, social worker, speech therapist, and healthcare professional.
Time frame: Week 1, Week 8, Week 16, Week 24
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
A 12-item assessment measuring mindfulness, distress, well-being, emotion-regulation, and problem-solving approaches. A Likert scale ranging from 1 (rarely/not at all) to 4 (almost always) with reverse scoring on items 2, 6 and 7.
Time frame: Week 1, Week 24
Pittsburgh Sleep Quality Index (PSQI)
The PSQI contains 19 self-rated questions and 5 questions rated by the bed partner or roommate (if one is available) that assesses self-rated sleep quality and disturbances over a 1-month time interval. Only self-rated questions are included in scoring. The 19 self-rated items are combined to form seven "component" scores, each of which has a range of 0-3 points. A score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty. The seven component scores are then added to yield one "global" score, with a range of 0-21 points. "0" indicating no difficulty and "21" indicating severe difficulties in all areas.
Time frame: Week 1, Week 24
ABC Plans
A 1-item measure to assess total quantity of ABC plans created. Options are 1 (1-3), 2 (4-6), 3 (7-9) or 4 (10 or more). Experimental group completes this measure on weeks 8, 16 and 24. Wait-list control group completes this measure on weeks 16 and 24.
Time frame: Week 8, Week 16, Week 24
Plan to share: Yes — De-identified IPD will be available upon request to our Alzheimer's Disease Research Center.
Supporting information: Study protocol
Time frame: Once data is available, it will be available indefinitely.
Access criteria: Requests need to be made to the PI at the Oregon Alzheimer's Disease Research Center (OARDC). A short data request form will need to be submitted.
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 285 non-industry interventional studies with no phase under Caregiver Burden, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 28 months is above that.
Counting every sponsor, half of 294 studies reached it within 16 months; a quarter within 7 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oregon Health and Science University →